All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

11

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 11 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Vancomycin HCl*

Vancomycin HCl

D$52.3M-21%172,023$304$3.53
Vancomycin HCl

Vancomycin/Water For Inj (PEG)

D$1.7M+38%5,996$291$0.09
Firvanq

Vancomycin HCl

D$510K-56%1,862$274$0.92
Vancomycin HCl-0.9% NaCl

Vancomycin/0.9 % Sod Chloride

D$422K-23%1,046$403$0.11
Vancocin HCl

Vancomycin HCl

D$418K-21%25$16,732$69.01
Vancomycin*

Vancomycin HCL In 5 % Dextrose* · J3370

B$159K-16%5,120$31$2.38
Vancomycin HCL (J3372)

Vancomycin/Water For Inj (Peg) · J3372

B$132K+7597%4,366$30$6.38
Vancomycin HCl

Vancomycin HCl In 5 % Dextrose

D$122K-24%347$351$0.14
Vancomycin HCL (J3371)

Vancomycin HCL · J3371

B$116K+24430%5,227$22$5.79
Vancomycin HCl-D5W

Vancomycin HCl In 5 % Dextrose

D$35K+320%102$340$0.12
Vancomycin

Vancomycin HCl In 5 % Dextrose

D$25K-19%164$150$0.09

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.